IDH1 and acute myeloid leukemia: Following maintenance regimens have been administered depending on AML molecular profile: FLT3 Inhibitors (midostaurin 50 mg twice daily or gilteritinib 120 mg/day), administered for 12 months; IDH1/2 inhibitors (ivosidenib 500 mg/day or enasidenib 100 mg/day), for 2 years; or hypomethylating agents (azacitidine 75 mg/m2, d1 to 5, every 28 days; or decitabine 20 mg/m2, days 1 to 5, every 28 days) +/− venetoclax 100–400 mg/day, days 1 to 7–21 days every 28 days, administered for 6 cycles.